版本:
中国

BRIEF-Bellerophon Therapeutics announces new data from phase 2 study

May 1 Bellerophon Therapeutics Inc

* Bellerophon therapeutics - announced new data from phase 2 study evaluating use of inopulse in idiopathic pulmonary fibrosis patients with pulmonary hypertension

* Bellerophon therapeutics-data show inopulse associated with clinically meaningful improvements in hemodynamics, exercise capacity in difficult-to-treat ph-ipf patients Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐